Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma.

McGahan L
Record ID 32016001022
English
Authors' recommendations: Although it is the first PD-L1 inhibitor to receive approval based on the tumour response rate and durability reported in cohort 2 of the phase II trial IMvigor 210, patients were not followed long enough to adequately determine the median duration of response (DOR), whether atezolizumab reduces mortality or prolongs survival for some or all responders, how treatment may affect disease progression or recurrence, or to identify all potential adverse events. Further studies are needed to examine patient reported outcomes (PROMs), patient reported experiences (PREMs), and quality of life measures to determine whether atezolizumab provides adequate clinical benefit in terms of improving the symptoms and severity of locally advanced and MUC.
Details
Project Status: Completed
URL for project: http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published: 2016
URL for published report: http://eprints.hta.lbg.ac.at/1104/1/DSD_HSO_Nr.61.pdf
URL for additional information: http://eprints.hta.lbg.ac.at/1104/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Transitional Cell
  • Urologic Neoplasms
  • Immune Checkpoint Inhibitors
  • Urinary Bladder Neoplasms
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.